95 related articles for article (PubMed ID: 12060122)
1. Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remission.
Faderl S; Thall PF; Kantarjian HM; Estrov Z
Br J Haematol; 2002 Jun; 117(4):869-74. PubMed ID: 12060122
[TBL] [Abstract][Full Text] [Related]
2. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.
Jabbour E; Kantarjian H; Ravandi F; Thomas D; Huang X; Faderl S; Pemmaraju N; Daver N; Garcia-Manero G; Sasaki K; Cortes J; Garris R; Yin CC; Khoury JD; Jorgensen J; Estrov Z; Bohannan Z; Konopleva M; Kadia T; Jain N; DiNardo C; Wierda W; Jeanis V; O'Brien S
Lancet Oncol; 2015 Nov; 16(15):1547-1555. PubMed ID: 26432046
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Ravandi F; O'Brien SM; Cortes JE; Thomas DM; Garris R; Faderl S; Burger JA; Rytting ME; Ferrajoli A; Wierda WG; Verstovsek S; Champlin R; Kebriaei P; McCue DA; Huang X; Jabbour E; Garcia-Manero G; Estrov Z; Kantarjian HM
Cancer; 2015 Dec; 121(23):4158-64. PubMed ID: 26308885
[TBL] [Abstract][Full Text] [Related]
4. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study.
Takeuchi J; Kyo T; Naito K; Sao H; Takahashi M; Miyawaki S; Kuriyama K; Ohtake S; Yagasaki F; Murakami H; Asou N; Ino T; Okamoto T; Usui N; Nishimura M; Shinagawa K; Fukushima T; Taguchi H; Morii T; Mizuta S; Akiyama H; Nakamura Y; Ohshima T; Ohno R
Leukemia; 2002 Jul; 16(7):1259-66. PubMed ID: 12094249
[TBL] [Abstract][Full Text] [Related]
5. Receipt of maintenance therapy is most predictive of survival in older acute lymphoblastic leukemia patients treated with intensive induction chemotherapy regimens.
Landsburg DJ; Stadtmauer E; Loren A; Goldstein S; Frey N; Nasta SD; Porter DL; Tsai DE; Perl AE; Hexner EO; Luger S
Am J Hematol; 2013 Aug; 88(8):657-60. PubMed ID: 23640768
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
Kantarjian H; Thomas D; O'Brien S; Cortes J; Giles F; Jeha S; Bueso-Ramos CE; Pierce S; Shan J; Koller C; Beran M; Keating M; Freireich EJ
Cancer; 2004 Dec; 101(12):2788-801. PubMed ID: 15481055
[TBL] [Abstract][Full Text] [Related]
7. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Faderl S; Kantarjian HM; Thomas DA; Cortes J; Giles F; Pierce S; Albitar M; Estrov Z
Leuk Lymphoma; 2000 Jan; 36(3-4):263-73. PubMed ID: 10674898
[TBL] [Abstract][Full Text] [Related]
8. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Daver N; Thomas D; Ravandi F; Cortes J; Garris R; Jabbour E; Garcia-Manero G; Borthakur G; Kadia T; Rytting M; Konopleva M; Kantarjian H; O'Brien S
Haematologica; 2015 May; 100(5):653-61. PubMed ID: 25682595
[TBL] [Abstract][Full Text] [Related]
9. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis.
Sasaki K; Jabbour EJ; Ravandi F; Short NJ; Thomas DA; Garcia-Manero G; Daver NG; Kadia TM; Konopleva MY; Jain N; Issa GC; Jeanis V; Moore HG; Garris RS; Pemmaraju N; Cortes JE; O'Brien SM; Kantarjian HM
Cancer; 2016 Dec; 122(23):3650-3656. PubMed ID: 27479888
[TBL] [Abstract][Full Text] [Related]
10. [Acute lymphoblastic leukemia: experience in adult patients treated with hyperCVAD and 0195 Protocol, at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Cohort 2003-2007].
Arteaga-Ortiz L; Buitrón-Santiago N; Rosas-López A; Rosas-Arzate G; Armengolt-Jiménez A; Aguayo A; López-Karpovitch X; Crespo-Solís E
Rev Invest Clin; 2008; 60(6):459-69. PubMed ID: 19378832
[TBL] [Abstract][Full Text] [Related]
11. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Short NJ; Jabbour E; Sasaki K; Patel K; O'Brien SM; Cortes JE; Garris R; Issa GC; Garcia-Manero G; Luthra R; Thomas D; Kantarjian H; Ravandi F
Blood; 2016 Jul; 128(4):504-7. PubMed ID: 27235138
[TBL] [Abstract][Full Text] [Related]
12. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol.
Hann I; Vora A; Harrison G; Harrison C; Eden O; Hill F; Gibson B; Richards S;
Br J Haematol; 2001 Apr; 113(1):103-14. PubMed ID: 11328289
[TBL] [Abstract][Full Text] [Related]
13. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia.
Kantarjian HM; Walters RS; Keating MJ; Smith TL; O'Brien S; Estey EH; Huh YO; Spinolo J; Dicke K; Barlogie B
J Clin Oncol; 1990 Jun; 8(6):994-1004. PubMed ID: 2189958
[TBL] [Abstract][Full Text] [Related]
14. Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia.
Huang J; Zhao H; Hong M; Zhu H; Zhu Y; Lian Y; Li S; Li J; Qian S
BMC Cancer; 2018 Dec; 18(1):1269. PubMed ID: 30567513
[TBL] [Abstract][Full Text] [Related]
15. Persistence of peripheral blood and bone marrow blasts during remission induction in adult acute lymphoblastic leukemia confers a poor prognosis depending on treatment intensity.
Cortes J; Fayad L; O'Brien S; Keating M; Kantarjian H
Clin Cancer Res; 1999 Sep; 5(9):2491-7. PubMed ID: 10499624
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of the HEAVD protocol for adult acute lymphoblastic leukaemia.
Bassan R; Battista R; D'Emilio A; Viero P; Dragone P; Dini E; Barbui T
Eur J Cancer; 1991; 27(4):441-7. PubMed ID: 1827718
[TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia.
Ravandi F; Jorgensen JL; O'Brien SM; Jabbour E; Thomas DA; Borthakur G; Garris R; Huang X; Garcia-Manero G; Burger JA; Ferrajoli A; Wierda W; Kadia T; Jain N; Wang SA; Konoplev S; Kebriaei P; Champlin RE; McCue D; Estrov Z; Cortes JE; Kantarjian HM
Br J Haematol; 2016 Feb; 172(3):392-400. PubMed ID: 26492205
[TBL] [Abstract][Full Text] [Related]
18. Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen.
Weiser MA; O'Brien S; Thomas DA; Pierce SA; Lam TP; Kantarjian HM
Cancer; 2002 Jan; 94(2):285-91. PubMed ID: 11900213
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of L86 and L97 protocols for adult acute lymphoblastic leukemia.
Koharazawa H; Kanamori H; Sakai R; Hashimoto C; Takemura S; Hattori M; Taguchi J; Fujimaki K; Tomita N; Fujita H; Fujisawa S; Harano H; Ogawa K; Motomura S; Maruta A; Ishigatsubo Y
Leuk Lymphoma; 2008 Nov; 49(11):2133-40. PubMed ID: 19021056
[TBL] [Abstract][Full Text] [Related]
20. Role of allogenic bone marrow transplantation in adolescent or adult patients with acute lymphoblastic leukaemia or lymphoblastic lymphoma in first remission.
De Witte T; Awwad B; Boezeman J; Schattenberg A; Muus P; Raemaekers J; Preijers F; Strijckmans P; Haanen C
Bone Marrow Transplant; 1994 Nov; 14(5):767-74. PubMed ID: 7889010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
